- Home
- PDO vs KARD Comparison
PDO vs KARD Comparison
Compare PDO & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PDO | KARD |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | PDO | KARD |
|---|---|---|
| Price | $12.61 | $20.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 677.7K | 185.2K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.37 | $19.58 |
| 52 Week High | $14.25 | $27.00 |
Technical Indicators
Market Signals| Indicator | PDO | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 47.67 |
| Support Level | $12.37 | $19.67 |
| Resistance Level | $13.20 | $24.82 |
| Average True Range (ATR) | 0.16 | 1.40 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 18.89 | 33.95 |
Price Performance
Historical ComparisonAbout PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.